Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CALM1 | P0DP23 | 3/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28031835 | 0.84 | LTA4H (0.53) | ABCB1L3MBTL1SIGMAR1LTA4HCA4 | |
| SCHEMBL5083307 | 0.82 | TSHR (0.47) | CYP19A1TSHRMAPK1CALM1AKR1B1 | |
| Bromide SCHEMBL16180511 | 0.81 | TSHR (0.46) | CYP19A1TSHRMAPK1CALM1AKR1B1 | |
| SCHEMBL18179854 | 0.80 | MEN1 (0.49) | L3MBTL1MAOBGAALTA4H | |
| SCHEMBL1972535 | 0.77 | CYP19A1 (0.66) | CYP19A1TSHRMAPK1CALM1AKR1B1 | |
| SCHEMBL13086387 | 0.75 | ALDH1A1 (0.46) | TSHRMAOBSIGMAR1 | |
| Hydrochloric Acid SCHEMBL28127090 | 0.73 | ALDH1A1 (0.44) | L3MBTL1MAOBGAA | |
| SCHEMBL5973660 | 0.72 | MAOB (0.57) | CALM1ABCB1MAOBSIGMAR1 | |
| Bromide SCHEMBL28593166 | 0.72 | TACR1 (0.48) | TSHRMAPK1ABCB1TACR1MAOB | |
| SCHEMBL9491787 | 0.72 | CYP19A1 (0.68) | CYP19A1TSHRCALM1AKR1B1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10004722-B2 | Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols | KANNALIFE SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170157097-A1 | METHOD FOR TREATING HEPATIC ENCEPHALOPATHY OR A DISEASE ASSOCIATED WITH FREE RADICAL MEDIATE STRESS AND OXIDATIVE STRESS WITH NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS | KANNALIFE SCIENCES, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170157097-A1 | METHOD FOR TREATING HEPATIC ENCEPHALOPATHY OR A DISEASE ASSOCIATED WITH FREE RADICAL MEDIATE STRESS AND OXIDATIVE STRESS WITH NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS | KANNALIFE SCIENCES, INC. | 2017-06-08 | — | — | US | disclosed |
| US-9611213-B2 | Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy | KANNALIFE SCIENCES, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160311769-A1 | NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPTHY | KANNALIFE SCIENCES, INC. | 2016-10-27 | — | — | US | disclosed |
| US-20150202335-A1 | TARGETED MOLECULAR IMAGING PROBE AND METHOD FOR IN VIVO MOLECULAR IMAGING | SHEN BAOZHONG (CN) | 2015-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157097-A1 | METHOD FOR TREATING HEPATIC ENCEPHALOPATHY OR A DISEASE ASSOCIATED WITH FREE RADICAL MEDIATE STRESS AND OXIDATIVE STRESS WITH NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS | TXNRD2, KEAP1, GOT2 | CYP19A1 1518/4885TSHR 3175/4885MAPK1 1444/4885 |
| US-20160311769-A1 | NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPTHY | EPHX1, DBH, EPHX2 | CYP19A1 2594/4885TSHR 3038/4885MAPK1 3104/4885 |
| US-20150202335-A1 | TARGETED MOLECULAR IMAGING PROBE AND METHOD FOR IN VIVO MOLECULAR IMAGING | GJB2, GJA1, GAP43 | CYP19A1 4722/4885TSHR 4266/4885MAPK1 1114/4885 |
| US-10004722-B2 | Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols | TXNRD2, KEAP1, GOT2 | CYP19A1 1518/4885TSHR 3175/4885MAPK1 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.